

Application No. 10/088,354  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1-10. (Cancelled)

11. (Currently amended) A compound of formula (IIB)



(IIB)

or a salt, ester, amide or prodrug thereof

where

X is O, or S, S(O) or S(O)<sub>2</sub>, NH or NR<sup>8</sup> where R<sup>8</sup> is hydrogen or C<sub>1-6</sub>alkyl,

Z is O or S,

R<sup>9</sup> is hydrogen or optionally substituted hydrocarbyl or optionally substituted heterocyclyl ethenyl, optionally substituted phenyl, optionally substituted pyridyl or optionally substituted furanyl where optional substituents for R<sup>9</sup> groups are C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkyl, halo or nitro,

R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy,

C<sub>1-4</sub>alkoxymethyl, di(C<sub>1-4</sub>alkoxy)methyl, C<sub>1-4</sub>alkanoyl, trifluoromethyl, cyano, amino, C<sub>2-6</sub>alkenyl,

C<sub>2-6</sub>alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3

heteroatoms, selected independently from O, S and N, which heterocyclic group may be

aromatic or non-aromatic and may be saturated and [[D]]linked via a ring carbon or nitrogen

atom<sup>[[D]]</sup> or unsaturated and [[I]]linked via a ring carbon atom<sup>[[D]]</sup>, and which phenyl, benzyl or

heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected

from hydroxy, halogeno, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkanoyloxy, trifluoromethyl, cyano, amino,

nitro, C<sub>2-4</sub>alkanoyl, C<sub>1-4</sub>alkanoylamino, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulphanyl, C<sub>1-4</sub>alkylsulphinyl,

C<sub>1-4</sub>alkylsulphonyl, carbamoyl, N-C<sub>1-4</sub>alkylcarbamoyl, N,N-di(C<sub>1-4</sub>alkyl)carbamoyl,

Application No. 10/088,354  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

aminosulphonyl, N-C<sub>1-4</sub>alkylaminosulphonyl, N,N-di(C<sub>1-4</sub>alkyl)aminosulphonyl, C<sub>1-4</sub>alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkoxyloxy, trifluoromethyl, cyano, amino, nitro and C<sub>1-4</sub>alkoxycarbonyl, R<sup>1</sup> is hydrogen, R<sup>4</sup> is hydrogen, halo, C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkoxy are independently selected from halogeno, cyano, nitro, C<sub>1-3</sub>alkylsulphonyl, N(OH)R<sup>12</sup> (wherein R<sup>12</sup> is hydrogen, or C<sub>1-3</sub>alkyl), or R<sup>14</sup>X<sup>1</sup> (wherein X<sup>1</sup> represents a direct bond, -O-, -CH<sub>2</sub>-, -OC(O)-, -C(O)-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sup>15</sup>C(O)-, -C(O)NR<sup>16</sup>-, -SO<sub>2</sub>NR<sup>17</sup>-, -NR<sup>18</sup>SO<sub>2</sub>- or -NR<sup>19</sup> (wherein R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> each independently represents hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl)), and R<sup>14</sup> is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy


and n is 0, or an integer of from 1 to 6,

R<sup>8a</sup> is halo, cyano, nitro, trifluoromethyl, C<sub>1-3</sub>alkyl, -NR<sup>12</sup>R<sup>13</sup> [(wherein R<sup>12</sup> and R<sup>13</sup>, which may be the same or different, each represents hydrogen or C<sub>1-3</sub>alkyl)]], or a group -X<sup>1</sup>R<sup>14</sup> [(wherein X<sup>1</sup> represents a direct bond, -O-, -CH<sub>2</sub>-, -OC(O)-, -C(O)-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sup>15</sup>C(O)-, -C(O)NR<sup>16</sup>-, -SO<sub>2</sub>NR<sup>17</sup>-, -NR<sup>18</sup>SO<sub>2</sub>- or -NR<sup>19</sup> [(wherein R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> each independently represents hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl)]], and R<sup>14</sup> is hydrogen or C<sub>1-5</sub>alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino including C<sub>1-3</sub>alkyl and trifluoromethyl; or -R<sup>9</sup>R<sup>38</sup> and wherein R<sup>38</sup> represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group linked via carbon or nitrogen with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>hydroxyalkyl, C<sub>1-4</sub>aminoalkyl, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>hydroxyalkoxy, oxo, cyano, C<sub>1-4</sub>alkyl, cyclopropyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxycarbonyl, di(C<sub>1-4</sub>alkyl)amino, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanol, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkoxy, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR<sup>39</sup>R<sup>40</sup>-, -NR<sup>41</sup>C(O)R<sup>42</sup> wherein R<sup>39</sup>, R<sup>40</sup>, R<sup>41</sup> and R<sup>42</sup>, which may be the same or different, each represents hydrogen, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl and a group -(-O-)<sub>f</sub>(C<sub>1-4</sub>alkyl)<sub>g</sub>ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C<sub>3-6</sub>cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C<sub>1-4</sub>alkyl; and wherein R<sup>9</sup> is a C<sub>1-8</sub>alkylene group optionally

Application No. 10/088,354  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

substituted by one or more substituents selected from hydroxy, halogeno and amino hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy;

and  $R^{67}$  is  $C_{1-8}$ alkoxy optionally substituted with a group  $X^1R^{38}$  [([)] wherein  $X^1$  represents a direct bond,  $O$ ,  $CH_2$ ,  $OC(O)$ ,  $C(O)$ ,  $S$ ,  $SO$ ,  $SO_2$ ,  $NR^{15}C(O)$ ,  $C(O)NR^{16}$ ,  $SO_2NR^{17}$ ,  $NR^{18}SO_2$  or  $NR^{19}$  (wherein  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$  and  $R^{19}$  each independently represents hydrogen,  $C_{1-3}$ alkyl or  $C_{1-3}$ alkoxy $C_{2-3}$ alkyl)), and  $R^{38}$  are as defined above is a pyridone-group, an aryl-group or an aromatic heterocyclic-group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, aryl or aromatic heterocyclic-group may be substituted by one or more functional groups or by a hydrocarbyl-group optionally substituted by one or more functional groups; or heterocyclyl groups, or by a heterocyclyl-group optionally substituted by one or more functional groups or hydrocarbyl groups, or  $R^{67}$  is 3-morpholinopropoxy; provided that  $R^{67}$  is other than unsubstituted alkoxy; or a compound of formula (IIIb)



(IIIb)


or a salt, ester, amide or prodrug thereof,

where  $X$ ,  $R^4$ ,  $R^5$  and  $R^7$  are as defined above, and  $R^{66}$  and  $R^{67}$  are as defined above provided that  $R^{67}$  is other than unsubstituted alkoxy; and  $R^{68}$  is benzyl or cyanobenzyl or  $R^{68}$  is optionally substituted phenyl, where the optional substituents include  $C_{1-3}$ alkyl groups as well as nitro and halo or  $R^{68}$  is ethynyl optionally substituted with trimethylsilyl groups, carboxy, or an  $C_{1-8}$ alkyl ester thereof;

or

a compound of formula (IVb)

Application No. 10/088,354  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005




(IVB)

or a salt, ester, amide or prodrug thereof,

where X, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined above, R<sup>5</sup> is a group of formula NR<sup>10</sup>R<sup>10'</sup> where R<sup>10</sup> and R<sup>10'</sup> are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R<sup>10</sup> and R<sup>10'</sup> together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further heteroatoms, or an azo group of formula N=N-R<sup>11</sup> where R<sup>11</sup> is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group, or R<sup>5</sup> is a group -N=NR<sup>11</sup> where R<sup>11</sup> is as defined above, and R<sup>6</sup> and R<sup>7</sup> are as defined above provided that R<sup>7</sup> is other than unsubstituted alkoxy;

or

a compound of formula (IVC)




(IVC)

or a salt, ester, amide or prodrug thereof,

where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and X are as defined in claim 1.

Application No. 10/088,854  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

12. (Currently amended) A method of preparing a compound according to claim 11, which comprises reacting a compound of formula (VII)







(VII)

where R<sup>1'</sup>, R<sup>2''</sup>, R<sup>3'</sup>, and R<sup>4'</sup> are respectively equivalent to a group R<sup>1</sup>, R<sup>66</sup>, R<sup>67</sup> and R<sup>4</sup> as defined in claim 11 or a precursor thereof, and R<sup>85</sup> is a leaving group, with a compound of formula (VIII)



(VIII)

where X, is as defined in claim 11, and R<sup>8''</sup> is selected from



where Z, n, R<sup>6</sup>, R<sup>7</sup> and R<sup>9</sup> are as defined in claim 11.

Application No. 10/088,854  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

~~R<sup>6</sup> is an optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy group, provided that R<sup>6</sup> is other than ethenyl substituted by a carboxy group or an amide or sulphonamide derivative thereof,  
 and R<sup>6a</sup> is halogen or a group of formula -NR<sup>10</sup>R<sup>10'</sup> where R<sup>10</sup> and R<sup>10'</sup> are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R<sup>10</sup> and R<sup>10'</sup> together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further heteroatoms, or an azo group of formula -N=N-R<sup>11</sup> where R<sup>11</sup> is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group.~~

13-14. (Canceled)

15. (Currently Amended) A pharmaceutical composition comprising a compound of formula (IIB), (IIB'), (IVB) or (IVC) as defined in claim 11, or a salt, ester, amide or prodrug thereof, in combination with a pharmaceutically acceptable carrier.

16. (Currently amended) A compound according to claim 11, ~~selected from:~~

~~a compound of formula (IIB) or a salt, ester, amide or prodrug thereof, wherein~~

~~wherein X is O, S, S(O) or S(O)<sub>2</sub>, or -NR<sup>8</sup> where R<sup>8</sup> is hydrogen or C<sub>1-6</sub>alkyl;~~

~~Z is O or S,~~

~~n is 0, or an integer from 1 to 6,~~

~~R<sup>1</sup> and R<sup>4</sup> are both hydrogen;~~

~~R<sup>9</sup> is hydrogen, ethenyl, optionally substituted phenyl, optionally substituted pyridyl, or optionally substituted furanyl where optional substituents for R<sup>9</sup> groups are C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkyl, halo or nitro,~~

~~R<sup>6</sup> and R<sup>7</sup> are independently selected from hydrogen, halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy,~~

~~C<sub>1-4</sub>alkoxymethyl, di(C<sub>1-4</sub>alkoxy)methyl, C<sub>1-4</sub>alkanoyl, trifluoromethyl, cyano, amino, C<sub>2-6</sub>alkenyl,~~

~~C<sub>2-6</sub>alkynyl, a phenyl group, a benzyl group or a 5-6 membered heterocyclic group with 1-3~~

~~heteroatoms, selected independently from O, S and N, which heterocyclic group may be~~

~~aromatic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or~~

~~unsaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may~~

~~bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno,~~

~~C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C<sub>2-4</sub>alkanoyl,~~

~~C<sub>1-4</sub>alkanoylamino, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkylsulphinyl, C<sub>1-4</sub>alkylsulphenyl,~~

Application No. 10/088,854  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

carbamoyl, N-(C<sub>1-4</sub>alkyl)carbamoyl, N,N-di(C<sub>1-4</sub>alkyl)carbamoyl, aminosulphenyl, N-(C<sub>1-4</sub>alkyl)aminosulphenyl, N,N-di(C<sub>1-4</sub>alkyl)aminosulphenyl, C<sub>1-4</sub>alkylsulphenylamine, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C<sub>1-4</sub>alkoxycarbonyl;  
 R<sup>66</sup> is halo, cyano, nitro, trifluoromethyl, C<sub>1-3</sub>alkyl, NR<sup>12</sup>R<sup>13</sup> (wherein R<sup>12</sup> and R<sup>13</sup>, which may be the same or different, each represent hydrogen or C<sub>1-3</sub>alkyl), or a group X<sup>1</sup>R<sup>14</sup> where X<sup>1</sup> represents a direct bond, O, CH<sub>2</sub>, OC(O), C(O), S, SO, SO<sub>2</sub>, NR<sup>15</sup>C(O), C(O)NR<sup>16</sup>, SO<sub>2</sub>NR<sup>17</sup>, NR<sup>18</sup>SO<sub>2</sub> or NR<sup>19</sup> (wherein R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>19</sup> each independently represent hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl) and R<sup>14</sup> is a group (1) where group (1) is hydrogen or C<sub>1-6</sub>alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino (including C<sub>1-3</sub>alkyl and trifluoromethyl); or a group (10) where group (10) is R<sup>8</sup>R<sup>38</sup> and wherein R<sup>38</sup> represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>hydroxyalkyl, C<sub>1-4</sub>aminoalkyl, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>hydroxyalkoxy, oxo, cyano, C<sub>1-4</sub>alkyl, cyclopropyl, C<sub>1-4</sub>alkylsulphenyl, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxycarbonyl, di(C<sub>1-4</sub>alkyl)amino, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkoxy, di(C<sub>1-4</sub>alkyl)aminoC<sub>1-4</sub>alkoxy, carboxy, carboxamide, trifluoromethyl, cyano, C(O)NR<sup>39</sup>R<sup>40</sup>, NR<sup>41</sup>C(O)R<sup>42</sup> (wherein R<sup>39</sup>, R<sup>40</sup>, R<sup>41</sup> and R<sup>42</sup>, which may be the same or different, each represents hydrogen, C<sub>1-4</sub>alkyl, hydroxyC<sub>1-4</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl) and a group -(O)-(C<sub>1-4</sub>alkyl)<sub>f</sub>ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C<sub>2-6</sub>cycloalkyl, aryl or 5-6 membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C<sub>1-4</sub>alkyl); and wherein R<sup>8</sup> is a C<sub>1-8</sub>alkylene group optionally substituted by one or more substituents selected from hydroxy, halogeno and amino;  
 and R<sup>67</sup> is 3-morpholinepropoxy;  
 or  
 a compound of formula (IIIb) or a salt, ester, amide or prodrug thereof,  
 wherein X, R<sup>1</sup>, R<sup>4</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>68</sup> are as defined above

Application No. 10/088,854  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

$R^{67}$  is  $C_{1-6}$ alkoxy optionally substituted with fluorine or a group  $X^1R^{38}$  in which  $X^1$  represents a direct bond,  $O$ ,  $CH_2$ ,  $OCC$ , carbonyl,  $S$ ,  $SO$ ,  $SO_2$ ,  $NR^{12}CO$ ,  $CONR^{12}$ ,  $SO_2NR^{12}$ ,  $NR^{12}SO_2$  or  $NR^{14}$  (wherein  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  each independently represents hydrogen,  $C_{1-3}$ alkyl or  $C_{1-3}$ alkoxy $C_{2-3}$ alkyl) and  $R^{38}$  represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{1-4}$ hydroxyalkyl,  $C_{1-4}$ aminoalkyl,  $C_{1-4}$ alkylamino,  $C_{1-4}$ hydroxyalkoxy, carboxy, trifluoromethyl, cyano,  $CONR^{39}R^{40}$  and  $NR^{41}COR^{42}$  (wherein  $R^{38}$ ,  $R^{40}$ ,  $R^{41}$  and  $R^{42}$ , which may be the same or different, each represents hydrogen,  $C_{1-4}$ alkyl or  $C_{1-3}$ alkoxy $C_{2-3}$ alkyl); wherein at least  $R^{67}$  is other than unsubstituted alkoxy;

and  $R^6$  is benzyl and cyanobenzyl or  $R^6$  is optionally substituted phenyl, where the optional substituents include  $C_{1-3}$ alkyl groups as well as nitro and halo or  $R^6$  is ethynyl optionally substituted with trimethylsilyl groups, carboxy, or an  $C_{1-6}$ alkyl ester thereof

or

a compound of formula (IVB) or a salt, ester, amide or prodrug thereof,

where  $X$ ,  $R^1$ ,  $R^4$ ,  $R^5$  and  $R^7$  are as defined in relation to formula (IIB) above

$R^{51}$  a group of formula  $NR^{10}R^{10'}$  where  $R^{10}$  and  $R^{10'}$  are independently selected from hydrogen, alkyl or heterocyclyl, or  $R^{10}$  and  $R^{10'}$  together with the nitrogen atom to which they are attached form a morpholine or tetrahydropyridyl or  $R^{51}$  is a group  $N=NR^{11}$  where  $R^{11}$  is alkyl or phenyl or heterocyclyl

and  $R^{68}$  and  $R^{67}$  are as defined in relation to formula (IIIB) above;

or

a compound of formula (IVC) or a salt, ester, amide or prodrug thereof,

where  $X$ ,  $R^1$ ,  $R^4$  are as defined in relation to formula (IIB) above

$R^2$  and  $R^3$  are independently selected from, halo, cyano, nitro, trifluoromethyl,

$C_{1-3}$ alkyl,  $NR^9R^{10}$  (wherein  $R^9$  and  $R^{10}$ , which may be the same or different, each represents

hydrogen or  $C_{1-3}$ alkyl), or  $X^1R^{14}$  (wherein  $X^1$  represents a direct bond,  $O$ ,  $CH_2$ ,  $OCC$ ,

carbonyl,  $S$ ,  $SO$ ,  $SO_2$ ,  $NR^{12}CO$ ,  $CONR^{12}$ ,  $SO_2NR^{12}$ ,  $NR^{12}SO_2$  or  $NR^{14}$  (wherein  $R^{12}$ ,

$R^{13}$  and  $R^{14}$  each independently represents hydrogen,  $C_{1-3}$ alkyl or  $C_{1-3}$ alkoxy $C_{2-3}$ alkyl), and  $R^{14}$  is

selected from one of the following groups:

1) hydrogen or  $C_{1-6}$ alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro or amino;



Application No. 10/088,854  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

- 2')  $C_{1-6}alkylX^2COR^{20}$  (wherein  $X^2$  represents  $O$  or  $NR^{21}$  (in which  $R^{20}$  represents hydrogen,  $C_{1-3}alkyl$  or  $C_{1-3}alkoxyC_{2-3}alkyl$ ) and  $R^{21}$  represents  $C_{1-3}alkyl$ ,  $NR^{22}R^{23}$  or  $OR^{24}$  (wherein  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  which may be the same or different each represents hydrogen,  $C_{1-3}alkyl$  or  $C_{1-3}alkoxyC_{2-3}alkyl$ );
- 3')  $C_{1-6}alkylX^3R^{25}$  (wherein  $X^3$  represents  $O$ ,  $S$ ,  $SO$ ,  $SO_2$ ,  $OCO$ ,  $NR^{26}CO$ ,  $CONR^{27}$ ,  $SO_2NR^{28}$ ,  $NR^{29}SO_2$  or  $NR^{30}$  (wherein  $R^{26}$ ,  $R^{27}$ ,  $R^{28}$ ,  $R^{29}$  and  $R^{30}$  each independently represents hydrogen,  $C_{1-3}alkyl$  or  $C_{1-3}alkoxyC_{2-3}alkyl$ ) and  $R^{25}$  represents hydrogen,  $C_{1-3}alkyl$ , cyclopentyl, cyclohexyl or a 5-6 membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from  $O$ ,  $S$  and  $N$ , which  $C_{1-3}alkyl$  group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and  $C_{1-4}alkoxy$  and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno,  $C_{1-4}alkyl$ ,  $C_{1-4}hydroxyalkyl$  and  $C_{1-4}alkoxy$ );
- 4')  $C_{1-6}alkylX^4C_{1-6}alkylX^5R^{31}$  (wherein  $X^4$  and  $X^5$  which may be the same or different are each  $O$ ,  $S$ ,  $SO$ ,  $SO_2$ ,  $NR^{32}C$ ,  $CONR^{33}$ ,  $SO_2NR^{34}$ ,  $NR^{35}SO_2$  or  $NR^{36}$  (wherein  $R^{32}$ ,  $R^{33}$ ,  $R^{34}$ ,  $R^{35}$  and  $R^{36}$  each independently represents hydrogen,  $C_{1-3}alkyl$  or  $C_{1-3}alkoxyC_{2-3}alkyl$ ) and  $R^{31}$  represents hydrogen or  $C_{1-3}alkyl$ );
- 5')  $R^{37}$  (wherein  $R^{37}$  is a 5-6 membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from  $O$ ,  $S$  and  $N$ , which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno,  $C_{1-4}alkyl$ ,  $C_{1-4}hydroxyalkyl$ ,  $C_{1-4}alkoxy$ ,  $C_{1-4}alkoxyC_{1-4}alkyl$  and  $C_{1-4}alkylsulphenyl(C_{1-4}alkyl)$ );
- 6')  $C_{1-6}alkylR^{37}$  (wherein  $R^{37}$  is as defined hereinbefore in (5'));
- 7')  $C_{2-6}alkenylR^{37}$  (wherein  $R^{37}$  is as defined hereinbefore in (5'));
- 8')  $C_{2-6}alkynylR^{37}$  (wherein  $R^{37}$  is as defined hereinbefore in (5'));
- 9')  $R^{38}$  (wherein  $R^{38}$  represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from  $O$ ,  $N$  and  $S$ , which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents on an available carbon atom selected from hydroxy, halogeno, amino,  $C_{1-4}alkyl$ ,  $C_{1-4}alkoxy$ ,  $C_{1-4}hydroxyalkyl$ ,  $C_{1-4}aminoalkyl$ ,  $C_{1-4}alkylamino$ ,  $C_{1-4}hydroxyalkoxy$ , carboxy, trifluoromethyl, cyano,  $CONR^{39}R^{40}$  and  $NR^{41}COR^{42}$  (wherein  $R^{39}$ ,  $R^{40}$ ,  $R^{41}$  and  $R^{42}$  which may be the same or different, each represents hydrogen,  $C_{1-4}alkyl$  or  $C_{1-3}alkoxyC_{2-3}alkyl$ );
- 10')  $C_{1-6}alkylR^{38}$  (wherein  $R^{38}$  is as defined hereinbefore in (9'));
- 11')  $C_{2-6}alkenylR^{38}$  (wherein  $R^{38}$  is as defined hereinbefore in (9'));
- 12')  $C_{2-6}alkynylR^{38}$  (wherein  $R^{38}$  is as defined hereinbefore in (9'));

Application No. 10/088,854  
 Amendment Dated 08/12/2005  
 Reply to Office Action of 03/14/2005

~~13') C<sub>1-6</sub>alkylX<sup>6</sup>R<sup>38</sup> (wherein X<sup>6</sup> represents O, S, SO, SO<sub>2</sub>, NR<sup>43</sup>CO, CONR<sup>44</sup>, SO<sub>2</sub>NR<sup>46</sup>, NR<sup>46</sup>SO<sub>2</sub> or NF<sup>47</sup> (wherein R<sup>43</sup>, R<sup>44</sup>, R<sup>45</sup>, R<sup>46</sup> and R<sup>47</sup> each independently represents hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl) and R<sup>38</sup> is as defined hereinbefore in (9'));~~  
~~14') C<sub>2-6</sub>alkenylX<sup>7</sup>R<sup>38</sup> (wherein X<sup>7</sup> represents O, S, SO, SO<sub>2</sub>, NR<sup>48</sup>CO, CONR<sup>49</sup>, SO<sub>2</sub>NR<sup>50</sup>, NR<sup>50</sup>SO<sub>2</sub> or NF<sup>52</sup> (wherein R<sup>48</sup>, R<sup>49</sup>, R<sup>50</sup>, R<sup>51</sup> and R<sup>52</sup> each independently represents hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl) and R<sup>38</sup> is as defined hereinbefore in (9'));~~  
~~15') C<sub>2-6</sub>alkynylX<sup>8</sup>R<sup>38</sup> (wherein X<sup>8</sup> represents O, S, SO, SO<sub>2</sub>, NR<sup>53</sup>CO, CONR<sup>54</sup>, SO<sub>2</sub>NR<sup>56</sup>, NR<sup>56</sup>SO<sub>2</sub> or NF<sup>57</sup> (wherein R<sup>53</sup>, R<sup>54</sup>, R<sup>56</sup>, R<sup>55</sup> and R<sup>57</sup> each independently represents hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl) and R<sup>38</sup> is as defined hereinbefore in (9'));~~  
~~16') C<sub>1-3</sub>alkylX<sup>9</sup>C<sub>1-3</sub>alkylR<sup>38</sup> (wherein X<sup>9</sup> represents O, S, SO, SO<sub>2</sub>, NR<sup>58</sup>CO, CONR<sup>59</sup>, SO<sub>2</sub>NR<sup>60</sup>, NR<sup>60</sup>SO<sub>2</sub> or NF<sup>62</sup> (wherein R<sup>58</sup>, R<sup>59</sup>, R<sup>60</sup>, R<sup>61</sup> and R<sup>62</sup> each independently represents hydrogen, C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxyC<sub>2-3</sub>alkyl) and R<sup>38</sup> is as defined hereinbefore in (9'));~~  
 and  
~~17') C<sub>1-3</sub>alkylX<sup>9</sup>C<sub>1-3</sub>alkylR<sup>37</sup> (wherein X<sup>9</sup> and R<sup>37</sup> are as defined hereinbefore in (5'))).~~

17. (new) A compound according to claim 11 wherein R<sup>67</sup> is 3-morpholinopropoxy.
18. (new) A compound according to claim 11 wherein R<sup>8</sup> and R<sup>7</sup> are independently selected from hydrogen, halo, C<sub>1-4</sub>alkoxy, cyano, trifluoromethyl or phenyl.
19. (new) A compound according to claim 11 wherein R<sup>6</sup> and R<sup>7</sup> are both hydrogen.
20. (new) A compound according to claim 11 wherein the prodrug is a phosphate or sulphate or an alkyl, aryl or aralkyl derivative thereof.
21. (new) A method of treating colorectal or breast cancer in a warm blooded animal comprising administering to said animal an effective amount of a compound according to claim 11 or a salt or prodrug thereof.